| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue, net | 139,352 | - |
| Cost of sales (excluding stock-based compensation) | 63,219 | - |
| Amortization - license & ip expense | 1,455 | - |
| Sales (excluding stock-based compensation) | 24,646 | - |
| Marketing (excluding stock-based compensation) | 8,221 | - |
| Research and development (excluding stock-based compensation) | 23,401 | - |
| General and administrative (excluding stock-based compensation) | 34,140 | - |
| Stock-based compensation expense | 19,059 | - |
| Other segment items | -12,326 | - |
| Net loss | -22,463 | -16,985 |
| Depreciation and amortization | 5,683 | 3,765 |
| Amortization of operating lease-right-of use assets | 3,249 | 2,107 |
| Stock-based compensation | 19,058 | 13,420 |
| Loss on disposal of property and equipment | -355 | -253 |
| Provision for (benefit from) credit losses | 102 | 52 |
| Provision for excess and obsolete inventory | 467 | 335 |
| Deferred income taxes | -5,019 | -2,392 |
| Loss on investments, accretion, and amortization, net | - | -3,108 |
| Gain on investments, accretion, and amortization, net | -4,461 | - |
| Interest expenses for accretion of the legal settlement liabilities | 433 | 292 |
| Trade accounts receivable | -6,514 | -7,101 |
| Inventories | 7,295 | 5,073 |
| Prepaid expenses and other assets | -695 | 419 |
| Trade accounts payable | 1,757 | 1,169 |
| Accrued expenses and other liabilities | -739 | 670 |
| Legal settlement liabilities | -840 | -588 |
| Operating lease liabilities | -3,276 | -2,197 |
| Deferred revenue | 1,865 | 1,581 |
| Net cash (used in) provided by operating activities | -3,915 | -17 |
| Purchases of marketable securities | -201,047 | -141,423 |
| Proceeds from maturities of marketable securities | 216,106 | 136,906 |
| Proceeds from sale of property and equipment | 57 | 56 |
| Purchase of property and equipment | 3,083 | 2,426 |
| Purchase of intangible assets | 74 | 76 |
| Net cash provided by (used in) investing activities | 11,959 | -6,961 |
| Repayment of loan | 1,805 | 1,660 |
| Proceeds from employee stock purchase plan | 703 | 703 |
| Payments for taxes related to net share settlement of equity awards | 402 | 231 |
| Proceeds from issuance of common stock under employee stock plans | 240 | 103 |
| Proceeds from line of credit | 4,166 | 2,075 |
| Payments for repurchase of shares | 15,108 | 15,137 |
| Net cash used in financing activities | -12,206 | -14,147 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -1,303 | -2,149 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -5,465 | -23,275 |
| Cash and cash equivalents at beginning of period | 98,745 | - |
| Cash and cash equivalents at end of period | 93,281 | - |
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)